35650
document
Randomized clinical study comparing Compeed cold sore patch to acyclovir cream 5 % in the treatment of herpes simplex labialis . BACKGROUND Hydrocolloid technology has been proven effective in treating dermal wounds . A previous study showed that a newly developed thin hydrocolloid patch [ Compeed cold sore patch ( CSP ) ] provided multiple wound-healing benefits across all stages of a herpes simplex labialis ( HSL ) outbreak . METHODS An assessment of CSP efficacy and safety was conducted in an international , multicentre , assessor-blinded study , which enrolled 728 subjects with a history of recurrent HSL . Of these , 351 experienced an HSL outbreak and were randomized to use CSP ( n = 179 ) or acyclovir cream 5 % ( n = 172 ) at the onset of symptoms until the lesion healed , for a maximum of 10 days . The primary end point was the subject 's global assessment of therapy ( SGAT ; 0-10 scale ; 0 = no response , 10 = excellent response ) . Multiple secondary end points included clinician-assessed healing time and subject assessment of lesion protection , noticeability and social embarrassment . RESULTS CSP and acyclovir were highly effective ( mean SGAT = 7.89 and 8.00 , respectively ) , with no significant difference observed ( P = 0.65 ) . The difference in healing times between products was not significant ( median , 7.57 days with CSP vs. 7.03 days with acyclovir , P = 0.37 ) . Both treatments were well tolerated . CONCLUSION CSP using hydrocolloid technology provides an efficacious and safe alternative to topical antivirals in treating HSL as a wound while affording additional immediate benefits of wound protection , discretion and relief of social embarrassment .
35651
Intervention_Pharmacological
Compeed cold sore patch
35652
Intervention_Pharmacological
acyclovir cream 5 %
35653
Intervention_Pharmacological
thin hydrocolloid patch [ Compeed cold sore patch ( CSP ) ]
35654
Intervention_Pharmacological
acyclovir cream 5 %
35655
Intervention_Pharmacological
CSP
35656
Intervention_Pharmacological
acyclovir
35657
Intervention_Pharmacological
CSP using hydrocolloid technology
35658
Outcome_Physical
subject 's global assessment of therapy
35659
Outcome_Physical
clinician-assessed healing time and subject assessment of lesion protection , noticeability and social embarrassment
35660
Outcome_Other
healing times between products
35661
Outcome_Other
efficacious and safe
35662
Participant_Condition
herpes simplex labialis .
35663
Participant_Condition
herpes simplex labialis
35664
Participant_Sample-size
728
35665
Participant_Condition
HSL
35666
Participant_Sample-size
351